BIG 1-14 / AURORAAim
To better understand the genetic aberrations in metastatic breast cancer and to discover the mechanisms of response or resistance to therapy, in order to ultimately identify the "right therapy for each individual patient". At the same time, patients with genetic aberrations that are being targeted by new drugs in development will be offered the possibility to participate in clinical trials, when approved and available in their countries.
An international, academically sponsored initiative to refine the knowledge on the biology of advanced/metastatic breast cancer and to determine how can such knowledge improve patient allocation to targeted therapy and potentially accelerate drug development in molecularly defined patient subsets.
The study is currently recruiting. The target accrual is 1,300 patients. Around 6 - 70 sites are expected to participate in AURORA.